Drug Guidance

Alectinib for adjuvant treatment of resectable, ALK mutation-positive non-small-cell lung cancer

-

Drug guidance

Asciminib for Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase after two or more tyrosine kinase inhibitors

-

Drug guidance

Atogepant and rimegepant for prophylaxis of migraine

-

Drug Guidance

Axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy

Drug guidance

Crisaborole ointment for treating atopic dermatitis

-

Drug guidance

Durvalumab in combination with tremelimumab for treating unresectable hepatocellular carcinoma

Drug guidance

Epcoritamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy

-

Drug guidance

Finerenone for treating chronic kidney disease and albuminuria associated with type 2 diabetes

-

Drug guidance

Fruquintinib for previously treated metastatic colorectal cancer

-

Drug guidance

Mavacamten for treating obstructive hypertrophic cardiomyopathy

-

Drug guidance